Bioavailability Study of Cretan Carob
Launched by HAROKOPIO UNIVERSITY · May 12, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well the body absorbs certain healthy compounds found in a drink made from Cretan carob powder, specifically from a variety called Imera. The researchers want to see how these compounds behave in healthy men after they consume the beverage. This study is currently looking for participants who are male, between the ages of 65 and 74, and have normal body fat.
To join the study, potential participants should be healthy and not have conditions like obesity, diabetes, heart disease, or any significant liver or kidney problems. They also should not be taking supplements for weight loss or be dietitians/nutritionists. If eligible, participants can expect to drink the carob beverage and provide feedback on their experience. This study aims to better understand the health benefits of carob and how it can fit into a healthy diet.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • healthy male adults
- • normal body fat mass
- Exclusion Criteria:
- • obesity (according to body fat mass)
- • Type 1 Diabetes, cardiovascular diseases, hypertension
- • thyroid disorder, liver disease, kidney disease
- • gastrointestinal disease
- • mental illness
- • use of nutraceutical supplements or natural products for weight loss
- • dietitians/nutritionists
About Harokopio University
Harokopio University, located in Athens, Greece, is a prominent academic institution dedicated to advancing research and education in various fields, including health sciences and nutrition. With a strong commitment to interdisciplinary collaboration, the university actively engages in clinical trials aimed at exploring innovative solutions to pressing health challenges. Through its rigorous research programs and partnerships with healthcare professionals, Harokopio University strives to contribute valuable insights to the scientific community and improve public health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Athens, , Greece
Patients applied
Trial Officials
Andriana C Kaliora
Principal Investigator
Harokopio University of Athens, Greece
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported